The compensatory activation of distinct pro-survival signaling pathways following mTOR inhibition suggests that these adaptive responses may drive tumor progression, highlighting the potential inadequacy of single-agent targeted therapies to control heterogeneous signaling networks within tumor populations. The gene discussed is MTOR; the disease is neoplasm.